SCHEMBL3767754

SCHEMBL3767754

CCOc1ccc(Br)cc1/C=C/C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 6/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.39
KMT2A Q03164 2/20 0.38
TSHR P16473 2/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C19 P33261 1/20 0.38
CTNNB1 P35222 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767758 1.00 GPR183 (0.41) GPR183SMN1; SMN2TDP1KMT2ATSHR
SCHEMBL3776067 0.91 TDP1 (0.44) GPR183SMN1; SMN2TDP1KMT2ATSHR
SCHEMBL3776062 0.91 TDP1 (0.44) GPR183SMN1; SMN2TDP1KMT2ATSHR
SCHEMBL13636007 0.91 SMN1; SMN2 (0.47) GPR183SMN1; SMN2TDP1TSHRHTT
SCHEMBL4381584 0.91 SMN1; SMN2 (0.47) GPR183SMN1; SMN2TDP1TSHRHTT
SCHEMBL4381901 0.90 SMN1; SMN2 (0.46) GPR183SMN1; SMN2TSHRHTTKDM4E
SCHEMBL14190929 0.90 SMN1; SMN2 (0.46) GPR183SMN1; SMN2TSHRHTTKDM4E
SCHEMBL3768039 0.87 KDM4E (0.48) SMN1; SMN2KMT2AALDH1A1GAAKDM4E
SCHEMBL3768034 0.87 KDM4E (0.48) SMN1; SMN2KMT2AALDH1A1GAAKDM4E
SCHEMBL13090286 0.85 SMN1; SMN2 (0.49) GPR183SMN1; SMN2KMT2ATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 GPR183 59/4885SMN1; SMN2 4282/4885TDP1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.